Literature DB >> 8619909

Differential effects of three dopamine receptor agonists in MPTP-treated monkeys.

N Arai1, M Isaji, H Miyata, J Fukuyama, E Mizuta, S Kuno.   

Abstract

The behavioral effects of cabergoline, pergolide and bromocriptine were investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys with attention to the induction of hyperactivity, as evidenced by irritability, excitability and aggressiveness. All three drugs improved the parkinsonism in a dose-dependent fashion following a single injection. Among the three dopamine (DA) receptor agonists used, the antiparkinsonian effect of pergolide was the strongest and had an immediate effect, while cabergoline showed the longest duration of the antiparkinsonian effect and was least potent in inducing hyperactivity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8619909     DOI: 10.1007/bf02256629

Source DB:  PubMed          Journal:  J Neural Transm Park Dis Dement Sect        ISSN: 0936-3076


  6 in total

1.  Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys.

Authors:  N Arai; M Isaji; M Kojima; E Mizuta; S Kuno
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Identification of neuroprotective compounds of caenorhabditis elegans dopaminergic neurons against 6-OHDA.

Authors:  Marketa Marvanova; Charles D Nichols
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

Review 3.  Clinical pharmacokinetics of cabergoline.

Authors:  Paolo Del Dotto; Ubaldo Bonuccelli
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Dopamine agonist 3-PPP fails to protect against MPTP-induced toxicity.

Authors:  Dhanasekaran Muralikrishnan; Manuchair Ebadi; Holly M Brown-Borg
Journal:  Neurochem Res       Date:  2004-02       Impact factor: 3.996

Review 5.  Cabergoline : a review of its use in the treatment of Parkinson's disease.

Authors:  Monique P Curran; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

Authors:  A Markham; P Benfield
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 6.497

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.